Immunogenicity of Human and Bovine Insulin in Type 1 Diabetes Mellitus Patients

Himanshu, M; Bhat, Chetan B.; Ramchandran, Sarita; Bhat, Kishor; Kumar, Prasanna K. M.

doi:10.1089/dia.2007.0294

Cited by 4 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upon retrospective analysis, we found that these antibodies appeared early, during the first 4-month trial after the end of the first month of leptin administration, and further increased thereafter. The appearance of antibodies following a substitutive hormonal therapy has been reported with other recombinant proteins (22)(23)(24)(25)(26)(27), and it can suggest some mechanisms for the resistance reported here. In type 1 diabetic patients, the production of antibodies against insulin is common but without reported clinical relevance, and has been observed with bovine, porcine, and recombinant insulin (25)(26)(27).…”

Section: Discussionsupporting

confidence: 75%

“…The appearance of antibodies following a substitutive hormonal therapy has been reported with other recombinant proteins (22)(23)(24)(25)(26)(27), and it can suggest some mechanisms for the resistance reported here. In type 1 diabetic patients, the production of antibodies against insulin is common but without reported clinical relevance, and has been observed with bovine, porcine, and recombinant insulin (25)(26)(27). Antibody production interfering with the treatment effect has been well documented in children with congenital GH deficiency (22)(23)(24).…”

Section: Discussionsupporting

confidence: 75%

See 1 more Smart Citation

Resistance to leptin-replacement therapy in Berardinelli–Seip congenital lipodystrophy: an immunological origin

Beltrand

Lahlou²,

Charpentier³

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

Context: Recently, in a 4-month proof-of-concept trial, beneficial metabolic effects were reported in non-diabetic children with Berardinelli-Seip congenital lipodystrophy (BSCL); this information prompted us to hypothesize that long-term leptin-replacement therapy might improve or reverse the early complications of the disease in these patients. Patients and methods: A 28-month trial was implemented in eight patients. Efficacy assessment was based on a decrease in serum triglyceride concentrations, and/or a decrease in liver volume and/or an increase in insulin sensitivity of at least 30% respectively. The response was defined as follows: total (3/3 positive criteria), partial (1 or 2/3), or negative (0/3). Anti-leptin antibodies were measured with a radiobinding assay, and a neutralizing effect was assessed in primary cultures of embryonic neurons incubated with an apoptotic agent (N-methyl-D-aspartate) and the patient serum, with or without leptin. Results: A negative or partial response to treatment was observed in five of eight patients even when leptin dosages were increased. A displaceable leptin binding was detectable in all patients after 2 months of treatment. At 28 months, binding was higher in the patients with a negative response than in the total responders, and it paralleled both the increase in leptin dosage and serum leptin concentrations. Co-incubation of embryonic neurons with serum from two patients with a negative response inhibited the neuroprotective effect of leptin. Conclusion: Under leptin therapy, patients with BSCL may develop a resistance to leptin, which could be partly of immunological origin, blunting the previously reported beneficial effects.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Discussionsupporting

confidence: 75%

Resistance to leptin-replacement therapy in Berardinelli–Seip congenital lipodystrophy: an immunological origin

Beltrand

Lahlou²,

Charpentier³

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

Current literature in diabetes

2009

Diabetes Metabolism Res

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of diabetes/metabolism. Each bibliography is divided into 26 sections: 1 Reviews; 2 General; 3 Genetics; 4 Epidemiology; 5 Immunology; 6 Obesity; 7 Prediction and Prevention; 8 Intervention: a) General; b) Care; c) Drug Therapy; d)Economics; e) Gene therapy; f) Nursing; g) Nutrition; h) Surgery; i) Transplantation; 9 Pathology and Complications: a) General; b) Cardiovascular; c) Eye disease; d) Gestational and fetal; e) Neurological; f) Podiatrical; g) Renal; 10 Endocrinology & Metabolism; 11 Experimental Studies; 12 Diagnosis and Techniques. Within each section, articles are listed in alphabetical order with respect to author

show abstract

W(h)ither Metreleptin for Lipodystrophy and the Metabolic Syndrome?

Mantzoros¹

2010

Endocrine Practice

View full text Add to dashboard Cite

Immunogenicity of Human and Bovine Insulin in Type 1 Diabetes Mellitus Patients

Abstract: Bovine and human insulins are antigenic, and there is no significant difference in AIAB titer. Prospective studies are required to determine the long-term clinical significance of these antibodies.

Cited by 4 publications

References 22 publications

Resistance to leptin-replacement therapy in Berardinelli–Seip congenital lipodystrophy: an immunological origin

Resistance to leptin-replacement therapy in Berardinelli–Seip congenital lipodystrophy: an immunological origin

Current literature in diabetes

W(h)ither Metreleptin for Lipodystrophy and the Metabolic Syndrome?

Contact Info

Product

Resources

About